The Beneficial Role of Some Bone Markers in Evaluating Women with Osteoporosis under Different Therapeutic Regimens

Shaima A. Abbass; Shatha H. Ali

doi:10.31351/vol20iss1pp1-7

Details

Publication Date

Wed Mar 29 2017

Journal Name

Iraqi Journal Of Pharmaceutical Sciences ( P-issn 1683 - 3597 E-issn 2521 - 3512)

Volume

20

Issue Number

1

DOI

10.31351/vol20iss1pp1-7

Choose Citation Style

Statistics

View publication

13

Abstract Views

729

Statistics

(1)

The Beneficial Role of Some Bone Markers in Evaluating Women with Osteoporosis under Different Therapeutic Regimens

Shaima A. Abbass

Shatha H. Ali

...Show More Authors

Osteoporosis is a systemic disease of the skeleton, characterized by low bone mass and alteration in the micro-architecture of the bone tissue that lead to an increase in brittleness with the ensuing predisposition to bone fracture. Global statistics shows that women are more exposed to this disease than men and in particular at menopause. This study was designed to evaluate the use of some bone markers: serum osteocalcin (Ost), alkaline phosphatase (ALP), as bone formation markers, also parathyroid hormone (PTH), calcium and inorganic phosphate level, for the assessment of patients with osteoporosis and to evaluate their role in monitoring of several types of therapeutic interventions (such as bisphosphonates, hormonal replacement therapy, and Ca and vit.D) in postmenopausal women.This study comprised of 36 women (age 51.67Â±5.14 years) those diagnosed to have osteoporosis, to be allocated randomly into three groups according to the type of therapy to be given as;

group A: received bisphosphonates (sodium alendronate 10mg/day) for twelve weeks (N=12).

group B: treated with hormonal replacement therapy (conjugated estrogen 0.625mg/day) for twelve weeks (N=12).

group C: received Ca and vit. D (Ca1500mg/day and cholecalciferol 1000IU/day) for twelve weeks(N=12).

In addition to 15 perimenopausal healthy women to serve as a control group (age 51.13Â±7.62 years).The studied parameters were measured in serum obtained before starting treatment and after 12 weeks of therapy. Result indicated that the baseline values of both serum Ost and ALP were significantly higher in postmenopausal patients as compared to controls and serum Ost showed a significant reduction after treatment with alendronate compared to those treated with either HRT or Ca and vit. D.From this study we recommend estimating the baseline bone markers (Ost and ALP) status for newly diagnosed osteoporotic patients to be used as a guide for deciding the initial therapeutic intervention, and detection of non responder instead of waiting until patients develop further fracture while they are on therapy.

Key words: Osteoporosis, Postmenopause, Osteocalcin, Alendronate

View Publication Preview PDF

Quick Preview PDF

Publication Date

Sat Sep 01 2018

Journal Name

Polyhedron

Novel dichloro (bis {2-[1-(4-methylphenyl)-1H-1, 2, 3-triazol-4-yl-κN3] pyridine-κN}) metal (II) coordination compounds of seven transition metals (Mn, Fe, Co, Ni, Cu, Zn and Cd)

The 1

3-dipolar cycloaddition “click” reaction between an azide and an alkyne to give a 1

2

3-triazole was reported by Huisgen in 1961 [1]. In 2002 the Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC) to prepare a 1

2

3-triazole was reported [2]

[3]. The existence of relatively basic nitrogen atoms in the 1

2

3-triazole rings

and the possibility of introducing additional donor groups in the substituents (Fig. 1)

made the CuAAC “click” reaction an attractive method to prepare differently substituted 1

2

3-triazoles. These compounds have been used as ligands to coordinate to various metal ions that display a range of applications such as in electrochemical and photochemical studies

in supramolecular chemistry

magnetism

metal-ion sensing and catalysis [4]. The reasons for the success of the “click” reaction

is that it is easy to carry out and is widely applicable. It is not affected by a variety of functional groups

and can be carried out with a variety of Cu(I) catalysts and solvents

including aqueous conditions. The Cu(I) catalysts overcome the high activation energy barrier of the non-catalyzed Huisgen reaction by changing the mechanism of the reaction. A large variety of copper catalysts can be used for the CuAAC reaction

on condition that the maximum concentration of Cu(I) species is generated during the reaction. The pre-catalyst can be a Cu(II) salt (usually CuSO4) together with a reducing agent (often sodium ascorbate) or a Cu(I) compound in the presence of a base or amine ligand and a reducing agent to prevent oxidation to Cu(II). Some strong oxidising cupric salts or complexes such as Cu(OAc)2 also work. The solvent is very flexible from organic to aqueous

with the most commonly used combination water + an alcohol (t-BuOH

MeOH or EtOH). The key role of the solvent or solvent mixture is to solubilize the substrates and Cu(I) catalyst in order to ensure rapid reactions. Such aqueous conditions are very useful for biochemical conjugations

as well as for organic syntheses. We recently reported on the synthesis of a series of differently substituted 1

2

3-triazole chromophores

the substituted 2-(1-phenyl-1H-1

2

3-triazol-4-yl)pyridine ligands [5]

see Fig. 2 middle

with substituents R = H (L1)

CH3 (L2)

OCH3 (L3)

COOH

F

Cl

CN

CF3

O(CH2)3CH3 and N(CH3)2. These versatile ligands were found to coordinate to various first row transition metals

such as manganese

cobalt and nickel [6]. Here we extend the series to include more first row transition metal(II) coordination compounds

iron

copper and zinc

as well as a second row transition metal(II) coordination compound

cadmium

containing the 2-(1-(4-methyl-phenyl)-1H-1

2

3-triazol-1-yl)pyridine chromophore (Fig. 2 right with R = CH3). This series of seven novel coordination compounds is the first series of pyridyl-triazole based transition metal coordination compounds where seven different transition metals are coordinated to the same 1

2

3-triazole chromophore

namely 2-(1-(4-methyl-phenyl)-1H-1

2

3-triazol-1-yl)pyridine.

Kinaan M

...Show More Authors

Preview PDF

Publication Date

Tue Dec 09 2025

Journal Name

Journal Of Computer-aided Molecular Design

Synthesis, characterization and density functional theory of a novel dichloro(2-(1-anthracene-9-ylmethyl)-1H-1,2,3-triazole-5-yl) pyridine)Cu(II) and polymeric dichloro(2-(1-anthracene-9-ylmethyl)-1H-1,2,3 -triazole-5-yl)pyridine) Cd(II) complexes

K. M.

Ahmed A.

S. J.

C.

J. H.

G. J.

Rasha Ahmed

Aly

Musa E. Mohamed

O. A.

Ali Y.

Ahmed A.

Sameera N.

Antar A.

...Show More Authors

View Publication

(1)

Publication Date

Thu Jan 01 2026

Journal Name

Chalcogenide Letters

Structural and Optical Properties of Cu2ZnSn(S1−xSex)4 Nanostructures Thin Film for Photovoltaic Applications

Cu2 ZnSn(S1−x Se x)4 thin film

energy gap

dielectric constant

extinction coefficient

refractive index

Bushra A.

Ameer J.

Ahmad A.

Yasser A.

...Show More Authors

Copper zinc tin sulfide selenide, Cu2 ZnSn(S1−x Se x)4 , absorbers are promising earth-abundant and environmentally benign materials for low-cost photovoltaic applications. This study investigates the structural and optical properties of Cu 2 ZnSn(S1−x Se x)4 nanostructured thin films prepared by pulsed laser deposition using melt-quenched targets with selenium compositions x = 0.0–1.0. X-ray diffraction revealed that films with low selenium content remained amorphous, whereas higher selenium incorporation promoted the formation of polycrystalline kesterite–stannite phases with preferred orientations along (112), (200), (220), and (312). The crystallite size increased from 12.3 to 17.9 nm as selenium reached x = 1.0, indicating enha

View Publication

(1)

1 2 3 4 ... 3000 3001 3002 3003